The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.
Feb 19, 2014
not rated yet | 0
A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.
Feb 17, 2014
5 / 5 (1) | 0